5-[2-(Thiophen-3-yl)pyridin-4-yl]-4-pyridin-2-yl-1,3-thiazol-2-amine | 446301-88-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[2-(Thiophen-3-yl)pyridin-4-yl]-4-pyridin-2-yl-1,3-thiazol-2-amine
• 英文别名: 4-Pyridin-2-yl-5-(2-thiophen-3-ylpyridin-4-yl)-1,3-thiazol-2-amine
• CAS: 446301-88-8
• 化学式: C₁₇H₁₂N₄S₂
• 分子量: 336.441
• InChiKey: USNKFDWQBQLEDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ＴＧＦ−β阻害剤としてのチアゾールアミンおよびその使用
  申请人：——

  公开号：JP2004524302A

  公开（公告）日：2004-08-12

  Ｒ１およびＲ２、ＸおよびＸ’が明細書中の記載と同意義である式（Ｉ）：【化１】で示される治療的に活性なチアゾール誘導体、その製造方法、治療における、特に形質転換成長因子β（ＴＧＦ−β）の過剰発現により特徴付けられる障害の治療または予防におけるその使用、およびかかる治療において用いるための医薬組成物に関する。

  根据式（I）具有治疗活性的噻唑衍生物：[化学 1]，其中 R1 和 R2、X 和 X' 与说明书中所述者同义；其生产方法；其在治疗中的用途，特别是在治疗以转化生长因子-β（TGF-β）过度表达为特征的疾病中的用途。转化生长因子-β（TGF-β）过度表达的疾病，以及用于此类治疗的药物组合物。
• Thiazolmines and their use as tgf-beta inhibitors
  申请人：——

  公开号：US20040077687A1

  公开（公告）日：2004-04-22

  Therapeutically active thiazole derivatives of formula (I) wherein R 1 and R 2 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor &bgr; (TGF-&bgr;), and pharmaceutical compositions for use in such therapy. 1

  具有治疗活性的式(I)噻唑衍生物 其中 R 1 和 R 2 如说明书中所定义，其制备工艺，其在治疗中的用途，特别是在治疗或预防以转化生长因子&bgr;（TGF-&bgr;）过度表达为特征的疾病中的用途，以及用于此类治疗的药物组合物。 1
• THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1355870A1

  公开（公告）日：2003-10-29
• EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS
  申请人：Ichida Justin

  公开号：US20120021519A1

  公开（公告）日：2012-01-26

  The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.
• TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20140120621A1

  公开（公告）日：2014-05-01

  In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGFβR) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGFβR inhibitor. Further described herein are kits for producing iPS cells using a TGFβR inhibitor.